ReviewMethodist DeBakey cardiovascular journal2025
Cardiac Allograft Vasculopathy: A Focus on Advances in Diagnosis and Management.
Review in Methodist DeBakey cardiovascular journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Graft rejection across solid organ transplants: mechanisms, monitoring, and immunosuppressive therapeutics.Frontiers in surgery · 2026Pooled it
- Percutaneous coronary intervention in cardiac allograft vasculopathy: From lesion selection to longitudinal graft management.JHLT open · 2026Review
- The gut microbiome and allograft outcomes: implications for heart transplantation.The Journal of clinical investigation · 2026Review
- Comparative Efficacy and Safety of Ivabradine vs. Beta Blockers in Heart Transplant Patients: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Lipofuscin: Wear Pigment or Alarm Signal for Cardiac AlloGraft Vasculopathy?Diagnostics (Basel, Switzerland) · 2026Article
- Drug-coated balloon treatment of in-stent restenosis in complex severe cardiac allograft vasculopathy.JHLT open · 2026Article
- Pulsatility as a Potential Regulator of Cardiovascular Biology: Molecular, Cellular, and Hemodynamic Remodeling During Continuous-Flow Left Ventricular Assist Device Support and Following Heart Transplantation.International journal of molecular sciences · 2026Review
- Abdominal Wall Erythema as a Suspected Extracardiac Manifestation of Cardiac Allograft Rejection.Cureus · 2026Article
- From the Bench to the Bedside and Back: Contemporary Applications of Basic Science to Innovations in Heart Transplantation.The Canadian journal of cardiology · 2026Review
- Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.Frontiers in cardiovascular medicine · 2026Review
- Vascular Remodeling in Chronic Rejection: Insights into Transplant Vasculopathy Across Solid Organ Allografts.Results and problems in cell differentiation · 2026Review
- Review
- A stage-based framework to interpret regulatory T cell biology after heart transplantation.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac allograft vasculopathy (CAV) is a type of coronary artery disease unique to heart transplant recipients that can result from chronic rejection of the transplanted heart. CAV is a major cause of morbidity and mortality after the first year of transplantation. Both immune and nonimmune mechanisms contribute to the initiation and progression of CAV and result in intimal thickening, fibrosis with luminal stenosis, chronic myocardial ischemia and eventual graft failure. Recent advances in imaging modalities-including invasive intracoronary imaging and noninvasive imaging with cardiac positron emission tomography-have improved the early detection of CAV and may allow for optimization of CAV-targeted therapies to reduce CAV progression and ultimately preserve graft function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.